Ambrx Biopharma Inc. (AMAM): Price and Financial Metrics
GET POWR RATINGS... FREE!
AMAM Price/Volume Stats
| Current price | $14.81 | 52-week high | $15.29 |
| Prev. close | $14.01 | 52-week low | $0.38 |
| Day low | $13.57 | Volume | 423,224 |
| Day high | $15.00 | Avg. volume | 3,042,361 |
| 50-day MA | $10.83 | Dividend yield | N/A |
| 200-day MA | $4.43 | Market Cap | 572.20M |
AMAM Stock Price Chart Interactive Chart >
AMAM POWR Grades
- Growth is the dimension where AMAM ranks best; there it ranks ahead of 83.04% of US stocks.
- The strongest trend for AMAM is in Quality, which has been heading up over the past 102 days.
- AMAM's current lowest rank is in the Stability metric (where it is better than 8.72% of US stocks).
AMAM Stock Summary
- AMAM's price/sales ratio is 87.96; that's higher than the P/S ratio of 97.32% of US stocks.
- Over the past twelve months, AMAM has reported earnings growth of 353.94%, putting it ahead of 95.26% of US stocks in our set.
- In terms of volatility of its share price, AMAM is more volatile than 98.81% of stocks we're observing.
- Stocks that are quantitatively similar to AMAM, based on their financial statements, market capitalization, and price volatility, are BLDP, RXRX, MIST, EXEL, and FULC.
- To check out AMBRX BIOPHARMA INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001836056.
AMAM Valuation Summary
- In comparison to the median Healthcare stock, AMAM's EV/EBIT ratio is 185.9% lower, now standing at -6.7.
- AMAM's EV/EBIT ratio has moved up 26.8 over the prior 23 months.
Below are key valuation metrics over time for AMAM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AMAM | 2023-05-01 | 74.0 | 4.6 | -7.0 | -6.7 |
| AMAM | 2023-04-28 | 71.9 | 4.5 | -6.8 | -6.5 |
| AMAM | 2023-04-27 | 71.7 | 4.5 | -6.8 | -6.5 |
| AMAM | 2023-04-26 | 67.7 | 4.3 | -6.4 | -6.1 |
| AMAM | 2023-04-25 | 72.6 | 4.6 | -6.9 | -6.6 |
| AMAM | 2023-04-24 | 77.1 | 4.8 | -7.3 | -7.0 |
Ambrx Biopharma Inc. (AMAM) Company Bio
Ambrx Biopharma Inc., a clinical-stage biologics company, focuses on discovering and developing engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 ADC, which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug (IND)-enabling studies for the treatment of renal cell carcinoma (RCC) and other cancers, as well as other multiple product candidates targeting immuno-oncology applications. In addition, it is developing ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the à and gamma receptors on the cytotoxic T cell; and ARX822, a fab-small molecule bispecific that is in preclinical development for cancers. The company has license agreements with NovoCodex, Bristol Myers Squibb Company, Agensys, Inc., Sino Biopharmaceutical Co., Ltd., University of California, BeiGene, Ltd., The Scripps Research Institute and The California Research Institute of Biomedical Research, AbbVie Inc., Astellas Pharma Inc., and Elanco Animal Health. Ambrx Biopharma Inc. was founded in 2003 and is based in La Jolla, California.
Latest AMAM News From Around the Web
Below are the latest news stories about AMBRX BIOPHARMA INC that investors may wish to consider to help them evaluate AMAM as an investment opportunity.
Ambrx Appoints Stephen Glover as Chairman of its Board of DirectorsSAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Stephen Glover has joined the Company’s Board of Directors as Chairman. Mr. Glover has extensive experience building successful biopharmaceutical companies, with a focus on pharmaceutical business strategy, corporate development, product development, commercialization, and business optimization. The Company’s former Chair, Katrin Rupalla, Ph.D., has resigned from Ambrx’s Board of Direc |
Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare ConferencesSAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the JMP Securities Life Sciences Conference and RBC Capital Markets Global Healthcare Conference taking place in New York City on May 16th and 17th, respectively. The presentations will focus on the status of Ambrx’s clinical development strategy and an update on the progress of its |
Ambrx Expands Leadership Team with Appointment of Andrew Aromando as Chief Operating OfficerSAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced the appointment of Andrew P. Aromando as Chief Operating Officer. Mr. Aromando brings over 30 years of experience across numerous functional areas in the biopharmaceutical industry, serving in senior executive roles focused on corporate development, clinical operations, and commercial strategy. He will be responsible for leading certain operational functions, as well as the Company’s busine |
Ambrx Presents New Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual MeetingSAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced new preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, held from April 14 to 19, 2023. Ambrx’s presentations highlight data from preclinical studies of ARX517, the only anti-PSMA ADC in clinical development, and ARX305, one of two anti-CD70 ADCs in active clinical development. A trial in progress update on APEX-01, Ambrx’s first-in-h |
7 Cheap Stocks That Are Worth Your AttentionFinding cheap stocks that are worth an investment can be tricky, but the Portfolio Grader is a tool you can use to narrow the field. |
AMAM Price Returns
| 1-mo | 53.71% |
| 3-mo | 151.44% |
| 6-mo | 2,985.42% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 552.42% |
| 2022 | -74.86% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...